FDA Panel Endorses New Alzheimer’s Drug After Accelerated Approval
The newest Alzheimer’s drug is on its way for full regulatory approval after a U.S. Food and Drug Administration (FDA) advisory panel voted that the drug was beneficial in slowing cognitive decline. The drug is expected to be fully approved by July 6, 2023.1 In clinical trials the drug, known as lecanemab, demonstrated a 27 […]